On the other hand, IL-1 blocking therapies (particularly anakinra) seem to act as antidiabetic drugs by improving beta cell dysfunction induced by a vicious cycle involving the release of excessive amounts of IL-1β from pancreatic beta cells in response to hyperglycemia and additional stimuli such as the generation of IAPP aggregates and increased circulating FFA levels. The gene discussed is IL1A; the disease is Hyperglycemia.